Artemether / Lumefantrine
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Lenacapavir Artemether/Lumefantrine | Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential increased risk of lumefantrine adverse effects |
If coadministering, monitor for lumefantrine adverse effects (e.g. QT prolongation) |
|||
| Darunavir Artemether / Lumefantrine 1000 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Clinical significance unknown |
No significant change |
80 / 480 mg | AUC decrease 16%; AUC increase 175% |
If coadministering monitor closely for anti- malarial efficacy and lumefantrine toxicity. Dose adjustment not established. |
| Nevirapine Artemether / Lumefantrine 612 | Red: Avoid combination | Do not coadminister: Reduced levels of arthemether / lumifantrine | artemether / lumefantrine 80 mg / 480 mg x 6 doses | Lumefantrine AUC increased 56%; Cmax increased 24%; half-life: no significant change; clearance: decreased 36% |
Use alternative agents |
||
| Nevirapine Artemether / Lumefantrine 611 | Red: Avoid combination | Do not coadminister: Reduced levels of arthemether / lumifantrine | Potentially increased treatment failure |
artemether / lumefantrine 80 / 480 mg | Lumefantrine AUC decreased 21%; Cmax decreased 30% |
Use alternative agents |
|
| Nevirapine Artemether / Lumefantrine 610 | Red: Avoid combination | Do not coadminister: Reduced levels of arthemether / lumifantrine | Potentially increased treatment failure |
artemether / lumefantrine 80 / 480 mg | Artemether AUC decreased 72%; Cmax decreased 61%; Lumefantrine AUC decreased 21%; Cmax decreased 30% |
Use alternative agents |
|
| Etravirine Artemether / Lumefantrine 562 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | Decreased antimalarial effects |
No significant change |
artemether / lumefantrine 80 / 480 mg | Artemether AUC decreased 38%; Lumefantrine AUC decreased 13% |
Use with caution; avoid if possible |
| Efavirenz Artemether / Lumefantrine 472 | Orange: Minimal data to guide interaction | Consider using alternative agents | Potentially compromised antimalarial activity |
artemether 20mg / lumefantrine 120 mg 4 tablets / dose for 6 doses total in 3 days | Aremether AUC decreased 79%, Lumefantrine AUC decreased 30%-56%. |
If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy. |
|
| Efavirenz Artemether / Lumefantrine 471 | Orange: Minimal data to guide interaction | Consider using alternative agents | Potentially compromised antimalarial activity |
EFV AUC decreased 17% |
artemether 20mg / lumefantrine 120 mg 4 tablets / dose for 6 doses total in 3 days | Aremether AUC decreased 51%, Cmax decreased 21% Lumefantrine AUC decreased 21%. |
If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy. |
| Efavirenz Artemether / Lumefantrine 470 | Orange: Minimal data to guide interaction | Consider using alternative agents | Potentially compromised antimalarial activity |
artemether 20mg / lumefantrine 120 mg 4 tablets / dose for 6 doses total in 3 days | Aremether AUC decreased 51%, Cmax decreased 21% Lumefantrine AUC decreased 21% |
If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy. |

